Symbols / AUPH $16.42 +3.79% Aurinia Pharmaceuticals Inc.

Healthcare • Biotechnology • Canada • NGM
AUPH Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Fundamentals
Scroll to Statements
Market Cap 2.18B Enterprise Value 1.78B Income 287.20M Sales 283.06M Book/sh 4.39 Cash/sh 2.99
Dividend Yield — Payout 0.00% Employees 128 IPO — P/E 7.93 Forward P/E 20.02
PEG — P/S 7.71 P/B 3.74 P/C — EV/EBITDA 13.12 EV/Sales 6.29
Quick Ratio 4.70 Current Ratio 5.25 Debt/Eq 12.87 LT Debt/Eq — EPS (ttm) 2.07 EPS next Y 0.82
EPS Growth 150.73% Revenue Growth 28.80% Earnings 2026-05-11 ROA 11.16% ROE 59.91% ROIC —
Gross Margin 76.98% Oper. Margin 55.68% Profit Margin 101.47% Shs Outstand 132.97M Shs Float 130.61M Short Float 8.90%
Short Ratio 8.99 Short Interest — 52W High 16.54 52W Low 7.29 Beta 1.52 Avg Volume 1.04M
Volume 1.16M Target Price $17.00 Recom Buy Prev Close $15.82 Price $16.42 Change 3.79%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.00
Mean price target
2. Current target
$16.42
Latest analyst target
3. DCF / Fair value
$12.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.42
Low
$15.00
High
$21.00
Mean
$17.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-03 down Leerink Partners Outperform → Market Perform $16
2025-11-07 up Jefferies Hold → Buy $21
2025-11-05 down RBC Capital Outperform → Sector Perform $15
2025-08-01 main RBC Capital Outperform → Outperform $9
2024-09-16 reit Cantor Fitzgerald Overweight → Overweight $10
2024-09-09 reit Cantor Fitzgerald Overweight → Overweight $10
2024-09-06 reit HC Wainwright & Co. Buy → Buy $13
2024-03-01 reit HC Wainwright & Co. Buy → Buy $13
2024-02-23 main Cantor Fitzgerald Overweight → Overweight $10
2024-02-22 main HC Wainwright & Co. Buy → Buy $13
2024-02-16 main RBC Capital Outperform → Outperform $8
2023-09-22 reit HC Wainwright & Co. Buy → Buy $15
2023-08-07 main HC Wainwright& Co. Buy → Buy $15
2023-07-06 reit Cantor Fitzgerald Overweight → Overweight $15
2023-05-03 reit HC Wainwright & Co. — → Buy $14
2023-02-23 reit RBC Capital — → Outperform $11
2023-01-04 main RBC Capital — → Outperform $11
2022-11-07 main HC Wainwright & Co. — → Buy $14
2022-11-04 main RBC Capital — → Outperform $10
2022-11-04 down Oppenheimer Outperform → Perform —
News
RSS: Latest AUPH news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-03 TANG KEVIN C Director — 900,000 $13.90 $12,688,806
2026-02-27 MILLER JOSEPH M Chief Financial Officer — 57,229 $0.00 $0
2026-02-27 GREENLEAF PETER S Chief Executive Officer — 196,403 $0.00 $0
2026-02-27 DONLEY MATTHEW MAXWELL Chief Operating Officer — 58,160 $0.00 $0
2026-02-27 ROBERTSON STEPHEN P General Counsel — 59,090 $0.00 $0
2026-02-27 KEENAN GREG Officer — 40,586 $0.00 $0
2026-01-02 MILLER JOSEPH M Chief Financial Officer — 49,038 $0.00 $0
2026-01-02 GREENLEAF PETER S Chief Executive Officer — 165,384 $0.00 $0
2026-01-02 DONLEY MATTHEW MAXWELL Chief Operating Officer — 54,166 $0.00 $0
2026-01-02 ROBERTSON STEPHEN P General Counsel — 48,558 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
283.06
+20.38%
235.13
+33.97%
175.51
+30.95%
134.03
Operating Revenue
283.06
+20.38%
235.13
+33.97%
175.51
+30.95%
134.03
Cost Of Revenue
32.66
+15.64%
28.25
+99.66%
14.15
+149.79%
5.66
Reconciled Cost Of Revenue
32.66
+15.64%
28.25
+99.66%
14.15
+149.79%
5.66
Gross Profit
250.39
+21.03%
206.88
+28.21%
161.37
+25.71%
128.37
Operating Expense
143.83
-23.68%
188.47
-25.52%
253.06
+5.51%
239.84
Research And Development
32.51
+56.39%
20.79
-58.13%
49.64
+10.34%
44.99
Selling General And Administration
101.79
-40.83%
172.03
-11.80%
195.04
-0.68%
196.37
Selling And Marketing Expense
3.21
-77.24%
14.09
-22.93%
18.29
—
General And Administrative Expense
98.59
-37.58%
157.93
-19.02%
195.04
-0.68%
196.37
Salaries And Wages
57.29
-45.37%
104.87
-12.08%
119.28
+7.88%
110.57
Other Gand A
41.30
-22.17%
53.06
-72.79%
195.04
-0.68%
196.37
Other Operating Expenses
9.53
+319.23%
-4.35
-151.88%
8.38
+650.16%
-1.52
Total Expenses
176.49
-18.56%
216.71
-18.90%
267.20
+8.84%
245.50
Operating Income
106.56
+478.54%
18.42
+120.09%
-91.69
+17.74%
-111.47
Total Operating Income As Reported
104.91
+2338.40%
-4.69
+94.89%
-91.69
+17.74%
-111.47
EBITDA
137.94
+334.75%
31.73
+150.32%
-63.05
+39.17%
-103.65
Normalized EBITDA
139.58
+154.56%
54.83
+186.97%
-63.05
+39.17%
-103.65
Reconciled Depreciation
19.45
+0.02%
19.45
+66.95%
11.65
+330.41%
2.71
EBIT
118.49
+864.64%
12.28
+116.44%
-74.69
+29.77%
-106.35
Total Unusual Items
-1.65
+92.87%
-23.11
0.00
0.00
Total Unusual Items Excluding Goodwill
-1.65
+92.87%
-23.11
0.00
0.00
Special Income Charges
-1.65
+92.87%
-23.11
0.00
0.00
Restructuring And Mergern Acquisition
1.65
-92.87%
23.11
0.00
0.00
Net Income
287.20
+4893.08%
5.75
+107.37%
-78.02
+27.88%
-108.18
Pretax Income
114.16
+1432.72%
7.45
+109.61%
-77.47
+27.16%
-106.35
Net Non Operating Interest Income Expense
9.24
-23.83%
12.13
-14.67%
14.22
+177.88%
5.12
Interest Expense Non Operating
4.33
-10.44%
4.83
+74.23%
2.77
0.00
Net Interest Income
9.24
-23.83%
12.13
-14.67%
14.22
+177.88%
5.12
Interest Expense
4.33
-10.44%
4.83
+74.23%
2.77
0.00
Interest Income Non Operating
13.57
-20.02%
16.97
-0.16%
17.00
+232.10%
5.12
Interest Income
13.57
-20.02%
16.97
-0.16%
17.00
+232.10%
5.12
Other Income Expense
-1.65
+92.87%
-23.11
—
—
Tax Provision
-173.04
-10303.13%
1.70
+207.80%
0.55
-69.86%
1.83
Tax Rate For Calcs
0.00
-7.78%
0.00
+8.43%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.35
+93.43%
-5.26
0.00
0.00
Net Income Including Noncontrolling Interests
287.20
+4893.08%
5.75
+107.37%
-78.02
+27.88%
-108.18
Net Income From Continuing Operation Net Minority Interest
287.20
+4893.08%
5.75
+107.37%
-78.02
+27.88%
-108.18
Net Income From Continuing And Discontinued Operation
287.20
+4893.08%
5.75
+107.37%
-78.02
+27.88%
-108.18
Net Income Continuous Operations
287.20
+4893.08%
5.75
+107.37%
-78.02
+27.88%
-108.18
Normalized Income
288.50
+1122.65%
23.60
+130.24%
-78.02
+27.88%
-108.18
Net Income Common Stockholders
287.20
+4893.08%
5.75
+107.37%
-78.02
+27.88%
-108.18
Diluted EPS
2.07
+5075.00%
0.04
+107.41%
-0.54
+28.95%
-0.76
Basic EPS
2.14
+5250.00%
0.04
+107.41%
-0.54
+28.95%
-0.76
Basic Average Shares
134.37
-6.07%
143.06
-0.12%
143.24
+0.93%
141.91
Diluted Average Shares
138.70
-5.13%
146.19
+2.07%
143.24
+0.93%
141.91
Diluted NI Availto Com Stockholders
287.20
+4893.08%
5.75
+107.37%
-78.02
+27.88%
-108.18
Amortization
—
—
—
—
Amortization Of Intangibles Income Statement
—
—
—
—
Depreciation Amortization Depletion Income Statement
—
—
—
—
Depreciation And Amortization In Income Statement
—
—
—
—
Line Item Trend 2023-12-31
Total Assets
548.06
Current Assets
424.80
Cash Cash Equivalents And Short Term Investments
350.49
Cash And Cash Equivalents
48.88
Other Short Term Investments
301.61
Receivables
24.09
Accounts Receivable
24.09
Inventory
39.70
Raw Materials
1.75
Work In Process
37.38
Finished Goods
0.58
Prepaid Assets
9.49
Other Current Assets
1.03
Total Non Current Assets
123.26
Net PPE
116.57
Gross PPE
118.48
Accumulated Depreciation
-1.91
Properties
0.00
Machinery Furniture Equipment
2.02
Construction In Progress
0.00
Other Properties
113.21
Leases
3.24
Goodwill And Other Intangible Assets
4.98
Other Intangible Assets
4.98
Investments And Advances
0.20
Non Current Deferred Assets
—
Non Current Deferred Taxes Assets
—
Other Non Current Assets
1.52
Total Liabilities Net Minority Interest
170.11
Current Liabilities
77.19
Payables And Accrued Expenses
55.19
Payables
5.13
Accounts Payable
4.33
Current Accrued Expenses
50.06
Total Tax Payable
0.67
Income Tax Payable
0.67
Current Debt And Capital Lease Obligation
15.60
Current Capital Lease Obligation
15.60
Current Deferred Liabilities
4.81
Current Deferred Revenue
4.81
Other Current Liabilities
1.59
Total Non Current Liabilities Net Minority Interest
92.92
Long Term Debt And Capital Lease Obligation
82.01
Long Term Capital Lease Obligation
82.01
Tradeand Other Payables Non Current
0.00
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Other Non Current Liabilities
3.31
Stockholders Equity
377.95
Common Stock Equity
377.95
Capital Stock
1,200.22
Common Stock
1,200.22
Share Issued
143.83
Ordinary Shares Number
143.83
Treasury Shares Number
0.00
Additional Paid In Capital
120.79
Retained Earnings
-942.32
Gains Losses Not Affecting Retained Earnings
-0.73
Other Equity Adjustments
-0.73
Total Equity Gross Minority Interest
377.95
Total Capitalization
377.95
Working Capital
347.61
Invested Capital
377.95
Total Debt
97.61
Capital Lease Obligations
97.61
Net Tangible Assets
372.98
Tangible Book Value
372.98
Dueto Related Parties Current
0.80
Dueto Related Parties Non Current
7.60
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
135.66
+205.62%
44.39
+232.66%
-33.46
+57.93%
-79.53
Cash Flow From Continuing Operating Activities
135.66
+205.62%
44.39
+232.66%
-33.46
+57.93%
-79.53
Net Income From Continuing Operations
287.20
+4893.08%
5.75
+107.37%
-78.02
+27.88%
-108.18
Depreciation Amortization Depletion
19.45
+0.02%
19.45
+66.95%
11.65
+330.41%
2.71
Depreciation
—
—
—
—
Amortization Cash Flow
—
—
—
—
Depreciation And Amortization
19.45
+0.02%
19.45
+66.95%
11.65
+330.41%
2.71
Amortization Of Intangibles
—
—
—
—
Other Non Cash Items
-0.20
-125.38%
0.79
+152.01%
-1.51
+6.02%
-1.61
Asset Impairment Charge
0.00
0.00
-100.00%
0.92
-74.88%
3.65
Deferred Tax
-176.19
0.00
0.00
—
Deferred Income Tax
-176.19
0.00
0.00
—
Operating Gains Losses
9.69
+263.87%
-5.91
-199.34%
5.95
—
Net Foreign Currency Exchange Gain Loss
9.69
+263.87%
-5.91
-199.34%
5.95
0.00
Change In Working Capital
-8.78
-261.22%
5.45
+197.15%
-5.61
+17.74%
-6.82
Change In Receivables
-4.91
+60.58%
-12.46
-17.43%
-10.61
-650.39%
1.93
Changes In Account Receivables
-4.91
+60.58%
-12.46
-17.43%
-10.61
-650.39%
1.93
Change In Inventory
-6.46
-1454.72%
0.48
+103.01%
-15.87
-74.92%
-9.07
Change In Prepaid Assets
5.52
+401.09%
-1.83
-141.69%
4.40
+282.99%
-2.40
Change In Payables And Accrued Expense
-6.53
-146.01%
14.19
+5.94%
13.39
+1816.17%
0.70
Change In Accrued Expense
-4.66
-134.92%
13.33
+9.68%
12.15
+715.16%
1.49
Change In Payable
-1.87
-317.91%
0.86
-30.65%
1.24
+256.57%
-0.79
Change In Account Payable
-1.87
-317.91%
0.86
-30.65%
1.24
+256.57%
-0.79
Change In Other Working Capital
3.67
-36.64%
5.79
+53.84%
3.76
+23.46%
3.05
Change In Other Current Assets
0.73
+2254.84%
0.03
+293.75%
-0.02
+95.59%
-0.36
Change In Other Current Liabilities
-0.80
-6.93%
-0.75
-11.44%
-0.67
-3.22%
-0.65
Investing Cash Flow
-32.77
-183.46%
39.26
+685.48%
-6.71
+88.94%
-60.63
Cash Flow From Continuing Investing Activities
-32.77
-183.46%
39.26
+685.48%
-6.71
+88.94%
-60.63
Net PPE Purchase And Sale
-0.25
+10.32%
-0.28
+60.86%
-0.72
-145.89%
-0.29
Purchase Of PPE
-0.25
+10.32%
-0.28
+60.86%
-0.72
-145.89%
-0.29
Capital Expenditure
-0.25
+10.32%
-0.28
+60.86%
-0.72
-145.89%
-0.29
Capital Expenditure Reported
—
—
—
0.00
Net Investment Purchase And Sale
-32.52
-182.14%
39.59
+573.69%
5.88
+109.85%
-59.68
Purchase Of Investment
-526.65
+3.51%
-545.83
-4.27%
-523.50
+0.09%
-523.99
Sale Of Investment
494.13
-15.59%
585.42
+10.59%
529.38
+14.01%
464.32
Net Intangibles Purchase And Sale
—
—
0.00
0.00
Purchase Of Intangibles
—
—
0.00
0.00
Net Other Investing Changes
—
-0.04
+99.64%
-11.86
-1689.44%
-0.66
Financing Cash Flow
-106.11
-116.15%
-49.09
-856.96%
-5.13
-310.85%
2.43
Cash Flow From Continuing Financing Activities
-106.11
-116.15%
-49.09
-856.96%
-5.13
-310.85%
2.43
Net Issuance Payments Of Debt
-13.14
-9.57%
-11.99
-19.59%
-10.03
0.00
Repayment Of Debt
-13.14
-9.57%
-11.99
-19.59%
-10.03
0.00
Long Term Debt Payments
-13.14
-9.57%
-11.99
-19.59%
-10.03
0.00
Net Long Term Debt Issuance
-13.14
-9.57%
-11.99
-19.59%
-10.03
0.00
Net Common Stock Issuance
-98.16
-143.93%
-40.24
0.00
0.00
Common Stock Payments
-98.16
-143.93%
-40.24
0.00
0.00
Repurchase Of Capital Stock
-98.16
-143.93%
-40.24
0.00
0.00
Proceeds From Stock Option Exercised
14.95
+61.23%
9.27
+29.22%
7.17
+106.56%
3.47
Net Other Financing Charges
-9.76
-59.18%
-6.13
-169.15%
-2.28
-119.13%
-1.04
Changes In Cash
-3.22
-109.32%
34.56
+176.29%
-45.30
+67.11%
-137.73
Beginning Cash Position
83.43
+70.71%
48.88
-48.10%
94.17
-59.39%
231.90
End Cash Position
80.21
-3.86%
83.43
+70.71%
48.88
-48.10%
94.17
Free Cash Flow
135.41
+206.99%
44.11
+229.05%
-34.18
+57.18%
-79.82
Interest Paid Supplemental Data
—
—
—
1.98
Income Tax Paid Supplemental Data
2.82
+28.94%
2.18
+340.32%
0.50
-74.94%
1.98
Amortization Of Securities
-10.18
+20.05%
-12.73
-4.86%
-12.14
-672.33%
-1.57
Common Stock Issuance
—
—
0.00
0.00
Issuance Of Capital Stock
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category